Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mixed lineage kinases (MLKs) are a subfamily of serine/threonine protein kinases that belong to the mitogen-activated protein kinase kinase kinase (MAP3K) family. They act as upstream activators in MAP kinase signaling pathways, specifically phosphorylating and activating MAP2Ks, which then activate downstream MAP kinases such as JNKs and p38s. MLKs play roles in regulating cell migration, invasion, cell cycle progression, apoptosis, and stress responses. They are implicated in diseases like Parkinson’s disease and Alzheimer’s disease due to their role in neuronal apoptosis via JNK pathway activation, and some members modulate tumorigenesis through effects on cell migration/invasion. Notable family members include MLK2, MLK3, and DLK.
Inhibition of kinase activity; modulation of T cell function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mixed Lineage Kinase.